ADMA Biologics Soars 10.55% Intraday: What's Driving the Surge?

Summary
• ADMA Biologics (ADMA) is up 10.55% intraday as of 7:17 PM on March 27, 2026, trading at $9.165.
• Turnover hits 18.6 million shares, surpassing the typical 8.1% turnover rate for the stock.
• The stock is currently trading below the 30D, 100D, and 200D moving averages, indicating a deeply oversold condition.
• With RSI at 16.5 and MACD in bearish territory, this rapid reversal suggests a possible short-term bounce or a larger trend shift.

ADMA’s Volatility Spikes on Short-Term Bounce Amid Deep Oversold Conditions
ADMA Biologics experienced a sharp intraday rally of 10.55% after trading significantly below its 30D, 100D, and 200D moving averages and hitting an RSI of 16.5—a level typically associated with extreme oversold conditions. The stock has spent much of its 52-week range trading between $7.21 and $25.67, and its current price of $9.165 sits near the lower end of the Bollinger Bands at $10.07. While no major company or sector news has triggered the move, the rapid reversal points to a likely accumulation pattern by institutional or retail traders capitalizing on deep value, coupled with a short-covering move amid declining put volatility.

Options Playbook: ADMA20260417C10 and ADMA20260417C12 for Leverage and Liquidity
• 200-day average: 16.8967 (far above current price)
• RSI: 16.5094 (extremely oversold)
• MACD: -1.4597 (bearish), Signal Line: -0.7591, Histogram: -0.7006
• Bollinger Bands: ADMA is currently trading near the lower band at 10.07, suggesting a strong bounce potential if the rally continues.
• Key Support/Resistance Levels: ADMA is trading below all major moving averages and near key support at 10.07–10.80 level (lower Bollinger Band).

The stock’s rapid intraday move presents a strong case for a short-term bounce trade, especially if the price holds above $9.10. Leveraged small-cap biotech ETFs like Direxion Daily S&P Biotech Bull 3X ETF (LABU) are down 9%, offering a high-risk countertrend short play. However, the focus remains on ADMA’s options chain.

• ADMA20260417C10
- Type: Call
- Strike Price: $10.00
- Expiration Date: April 17, 2026
- Implied Volatility: 154.25% (elevated, reflecting high volatility)
- Delta: 0.4939 (moderate sensitivity to price movement)
- Theta: -0.0386 (high time decay, suitable for short-term)
- Gamma: 0.1141 (high sensitivity to underlying price movement)
- Turnover: 1,741,540 (extremely liquid)
- Leverage Ratio: 8.39%
- Implied Volatility is in a reasonable range for leveraged positions; Gamma and Theta suggest it reacts quickly to price swings and decays fast, ideal for active traders. With high turnover, this contract is highly tradable and offers leverage in a moderate delta range. If ADMA breaks $10, this option could experience a significant capital gain.

• ADMA20260417C12
- Type: Call
- Strike Price: $12.00
- Expiration Date: April 17, 2026
- Implied Volatility: 165.18% (elevated)
- Delta: 0.3308 (moderate)
- Theta: -0.0356 (high time decay)
- Gamma: 0.0968 (responsive to price movement)
- Turnover: 7,735 (good liquidity)
- Leverage Ratio: 13.19%
- This contract offers a high leverage ratio and reacts quickly to price swings. It is ideal for aggressive bulls expecting ADMA to continue rising. Given the high IV and moderate delta, it could offer a favorable risk-reward profile in a continued rally.

If ADMA breaks above $10, ADMA20260417C10 is the most compelling leveraged call to target. For a more speculative angle, ADMA20260417C12 offers high leverage and a clear directional bet.

Backtest ADMA Biologics Stock Performance
The ADMA strategy demonstrated positive performance following a 11% intraday increase from 2022 to the present date. The backtest results reveal a 3-day win rate of 53.88%, a 10-day win rate of 56.90%, and a 30-day win rate of 66.16%. The average returns over these periods were 0.62% over 3 days, 2.45% over 10 days, and 7.19% over 30 days, indicating a favorable trend. The maximum return during the backtest was 14.03%, which occurred on day 59, highlighting the strategy's potential for capturing significant gains after the intraday surge.

ADMA’s Oversold Rally Warrants a Tactical Buy for Short-Term Bounce Plays
ADMA Biologics is experiencing a sharp intraday rebound after hitting an extreme oversold condition, and with RSI at 16.5 and MACD in bearish territory, the move could either represent a short-term bounce or the start of a reversal. Traders should watch for ADMA to hold above $9.10 and confirm a break above $9.80 to validate the reversal. With Merck (MRK) up 0.89%, the broader biotech sector is not in a deep sell-off, which provides a modest tailwind. Investors are advised to consider a tactical long on ADMA20260417C10 for a short-term rally trade and monitor key levels around $10.00 and $12.00 for confirmation of a larger trend shift. If ADMA breaks above $10.00 and holds, it could signal a more durable reversal in the stock’s bearish trend.